Repligen Corp., of Waltham, Mass., received approval from the FDA to initiate a Phase I trial of RG3039, a potential treatment for spinal muscular atrophy, an inherited neurodegenerative disease. The company said the double-blind study will evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in as many as 40 healthy volunteers.